PMC:7195088 / 19184-19353
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
666 | 146-154 | Species | denotes | patients | Tax:9606 |
773 | 16-35 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
774 | 40-58 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
775 | 63-82 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
776 | 111-121 | Chemical | denotes | remdesivir | MESH:C000606551 |
928 | 160-168 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T95 | 160-168 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T177 | 16-35 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T178 | 16-25 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T179 | 26-35 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T180 | 40-58 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T181 | 63-82 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T182 | 63-72 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T183 | 73-82 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T184 | 88-98 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T185 | 99-103 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T186 | 111-121 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T132 | 0-169 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. |